JP2018517415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517415A5 JP2018517415A5 JP2017564059A JP2017564059A JP2018517415A5 JP 2018517415 A5 JP2018517415 A5 JP 2018517415A5 JP 2017564059 A JP2017564059 A JP 2017564059A JP 2017564059 A JP2017564059 A JP 2017564059A JP 2018517415 A5 JP2018517415 A5 JP 2018517415A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- cell
- cells
- receptor
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021036808A JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2023025723A JP7836780B2 (ja) | 2015-06-10 | 2023-02-22 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173701P | 2015-06-10 | 2015-06-10 | |
| US62/173,701 | 2015-06-10 | ||
| US201662337044P | 2016-05-16 | 2016-05-16 | |
| US62/337,044 | 2016-05-16 | ||
| PCT/US2016/036991 WO2016201304A1 (en) | 2015-06-10 | 2016-06-10 | Modified nk-92 cells for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036808A Division JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018517415A JP2018517415A (ja) | 2018-07-05 |
| JP2018517415A5 true JP2018517415A5 (https=) | 2019-06-27 |
Family
ID=57504144
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564059A Pending JP2018517415A (ja) | 2015-06-10 | 2016-06-10 | がんを処置するための改変ｎｋ−９２細胞 |
| JP2021036808A Active JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2023025723A Active JP7836780B2 (ja) | 2015-06-10 | 2023-02-22 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A Pending JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036808A Active JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2023025723A Active JP7836780B2 (ja) | 2015-06-10 | 2023-02-22 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A Pending JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10738279B2 (https=) |
| EP (3) | EP4424326A3 (https=) |
| JP (4) | JP2018517415A (https=) |
| KR (4) | KR20250027585A (https=) |
| CN (2) | CN113502270B (https=) |
| AU (1) | AU2016275030B2 (https=) |
| CA (1) | CA2987290C (https=) |
| ES (1) | ES2958720T3 (https=) |
| IL (2) | IL255884B2 (https=) |
| WO (1) | WO2016201304A1 (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2945320A1 (en) | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| EP4424326A3 (en) | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| SG11201810640RA (en) * | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| KR102528384B1 (ko) * | 2017-01-06 | 2023-05-02 | 이뮤너티바이오, 인크. | 감소된 cd96/tigit 발현을 갖는 유전자 변형된 nk-92 세포 |
| KR20190102259A (ko) * | 2017-01-10 | 2019-09-03 | 인트렉손 코포레이션 | 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절 |
| CA3051866A1 (en) * | 2017-02-01 | 2018-08-09 | Nant Holdings Ip, Llc | Calreticulin-mediated cancer treatment |
| CA3054078A1 (en) * | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding cd33, nkg2d and cd16 |
| KR102769529B1 (ko) | 2017-03-08 | 2025-02-19 | 이뮤너티바이오, 인크. | 임상용 변형된 NK-92 haNK003 세포 |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| EP3601538A4 (en) * | 2017-03-27 | 2021-03-10 | Nantcell, Inc. | ANK AND IL-12 COMPOSITIONS AND METHODS |
| BR112019020909A2 (pt) * | 2017-04-05 | 2020-05-12 | Korea Research Institute Of Bioscience And Biotechnology | Proteína de fusão ativadora de célula nk, célula nk e composição farmacêutica incluindo a mesma |
| EP4317422A3 (en) * | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| TWI676483B (zh) * | 2017-08-06 | 2019-11-11 | 強普生技股份有限公司 | 醫藥套組及其用途 |
| EP3697438A4 (en) | 2017-10-18 | 2021-08-18 | Intrexon Corporation | POLYPEPTIDE COMPOSITIONS WITH SPACERS |
| US12053490B2 (en) | 2017-10-26 | 2024-08-06 | St. Jude Children's Research Hospital, Inc. | Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells |
| WO2019089813A1 (en) * | 2017-11-01 | 2019-05-09 | Nantkwest, Inc. | Nk-92 cells to stimulate anti-cancer vaccine |
| CN111788301A (zh) * | 2017-11-24 | 2020-10-16 | 昂克治疗有限公司 | 靶向肿瘤细胞的经修饰的自然杀伤细胞和自然杀伤细胞系 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2019127215A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof |
| CN110028589B (zh) * | 2018-02-07 | 2023-07-21 | 阿思科力(苏州)生物科技有限公司 | 嵌合抗原受体、表达该嵌合抗原受体的nkg2d car-nk细胞及其制备方法和应用 |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN112004829A (zh) | 2018-03-12 | 2020-11-27 | 南克维斯特公司 | Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途 |
| WO2019182425A1 (ko) * | 2018-03-23 | 2019-09-26 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| IL321548A (en) | 2018-05-22 | 2025-08-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
| WO2020028656A1 (en) | 2018-08-01 | 2020-02-06 | Nantkwest, Inc. | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies |
| US12498363B2 (en) | 2018-08-01 | 2025-12-16 | Immunitybio, Inc. | Combined invasion and cytotoxicity assay using chemokine secreting target cells |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| KR102665280B1 (ko) * | 2018-10-31 | 2024-05-10 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거 |
| KR20240162586A (ko) | 2018-10-31 | 2024-11-15 | 난트퀘스트, 인크. | Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거 |
| IL316887A (en) * | 2018-11-06 | 2025-01-01 | Immunitybio Inc | NK-92 cells with chimeric antigen receptor modification |
| US12109238B2 (en) | 2018-11-06 | 2024-10-08 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN121518401A (zh) * | 2018-11-26 | 2026-02-13 | 免疫生物公司 | 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞 |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2020205100A1 (en) | 2019-03-15 | 2020-10-08 | Nantcell, Inc. | Recombinant eril-15 nk cells |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| EP4003376A4 (en) * | 2019-07-26 | 2023-09-06 | Nantkwest, Inc. | CD16+NK-92 CELLS PRELOADED WITH ANTIBODIES AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS |
| CN113574169A (zh) * | 2019-08-01 | 2021-10-29 | 南克维斯特公司 | 抗b7-h4嵌合抗原受体修饰的nk-92细胞 |
| KR20210033436A (ko) * | 2019-09-18 | 2021-03-26 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| US20210106619A1 (en) * | 2019-10-10 | 2021-04-15 | Nantkwest, Inc. | NK-92 Bone and Brain targeting |
| EP4061385A4 (en) * | 2019-11-19 | 2024-08-14 | Acibadem Mehmet Ali Aydinlar Üniversitesi | METHOD FOR REDESIGNING AND EXPANDING NK92 CELLS FOR USE IN IMMUNOTHERAPY |
| AU2020387167B2 (en) * | 2019-11-20 | 2024-10-24 | Immunitybio, Inc. | Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment |
| CN113646435A (zh) * | 2019-12-09 | 2021-11-12 | 南克维斯特公司 | 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆 |
| EP4097219A4 (en) * | 2020-01-28 | 2023-10-11 | ImmunityBio, Inc. | Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| CN115397973A (zh) * | 2020-01-30 | 2022-11-25 | 免疫生物公司 | 表达car的nk细胞消除bcma阳性恶性肿瘤 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US20230074303A1 (en) * | 2020-03-28 | 2023-03-09 | Board Of Regents, The University Of Texas System | Cell immunotherapy for the treatment of cancer |
| CA3184940A1 (en) | 2020-07-07 | 2022-01-13 | Jennifer Donglan WU | Mic antibodies and binding agents and methods of using the same |
| IL302335A (en) * | 2020-10-26 | 2023-06-01 | Res Inst Nationwide Childrens Hospital | NK cells with chimeric antigen receptor (CAR) and uses thereof |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| WO2024236557A1 (en) | 2023-05-12 | 2024-11-21 | Gilboa Therapeutics LTD | Compositions comprising an fc domain for the treatment of medical conditions |
| WO2025158400A1 (en) * | 2024-01-24 | 2025-07-31 | Yale University | Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034332B2 (en) | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| AU7267398A (en) | 1997-04-30 | 1998-11-24 | Hans Klingemann | Natural killer cell lines and methods of use |
| WO1999024566A1 (en) | 1997-11-06 | 1999-05-20 | Roche Diagnostics Gmbh | Tumor-specific antigens, methods for their production and their use for immunization and diagnosis |
| WO2000020460A1 (en) | 1998-10-05 | 2000-04-13 | Ludwig Institute For Cancer Research | Methods for producing human tumor antigen specific antibodies |
| US7098008B2 (en) | 2000-04-25 | 2006-08-29 | Ic&G Do. Ltd. | Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use |
| SE526227C2 (sv) * | 2002-05-15 | 2005-08-02 | North China Pharmaceutical Group | Metod för rening av rekombinant humant serumalbumin |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| WO2006004518A1 (en) | 2004-07-02 | 2006-01-12 | Avaris Ab | Method for the genetic activation of cells and uses of said cells |
| DE602005016683D1 (de) | 2004-07-10 | 2009-10-29 | Fox Chase Cancer Ct | Genetisch modifizierte, menschliche, natürliche killerzellenlinien: |
| US8946385B2 (en) * | 2007-01-30 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Chimeric Fcγ receptor and method for determination of ADCC activity by using the receptor |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| WO2011163401A2 (en) | 2010-06-22 | 2011-12-29 | Neogenix Oncology, Inc. | Colon and pancreas cancer specific antigens and antibodies |
| ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013051718A1 (ja) | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| CN104769103B (zh) | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | 多链嵌合抗原受体和其用途 |
| AU2013327136A1 (en) * | 2012-10-02 | 2015-04-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| EP3447072A3 (en) * | 2013-03-05 | 2019-05-22 | Baylor College of Medicine | Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN115028735A (zh) * | 2013-05-03 | 2022-09-09 | 俄亥俄州创新基金会 | Cs1-特异性嵌合抗原受体工程化的免疫效应细胞 |
| CN104561069A (zh) * | 2013-10-23 | 2015-04-29 | 深圳先进技术研究院 | 含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 |
| EP4134085B1 (en) * | 2013-11-01 | 2026-04-29 | ImmunityBio, Inc. | Tumoricidal and antimicrobial compositions and methods |
| US20160296562A1 (en) * | 2013-11-21 | 2016-10-13 | Ucl Business Plc | Cell |
| EP4424326A3 (en) | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| KR102665280B1 (ko) * | 2018-10-31 | 2024-05-10 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거 |
-
2016
- 2016-06-10 EP EP24185893.5A patent/EP4424326A3/en active Pending
- 2016-06-10 JP JP2017564059A patent/JP2018517415A/ja active Pending
- 2016-06-10 CN CN202110790574.3A patent/CN113502270B/zh active Active
- 2016-06-10 CA CA2987290A patent/CA2987290C/en active Active
- 2016-06-10 IL IL255884A patent/IL255884B2/en unknown
- 2016-06-10 IL IL309167A patent/IL309167A/en unknown
- 2016-06-10 US US15/531,109 patent/US10738279B2/en active Active
- 2016-06-10 EP EP16808427.5A patent/EP3307876B1/en active Active
- 2016-06-10 EP EP23176181.8A patent/EP4272757A3/en active Pending
- 2016-06-10 AU AU2016275030A patent/AU2016275030B2/en active Active
- 2016-06-10 KR KR1020257004508A patent/KR20250027585A/ko active Pending
- 2016-06-10 KR KR1020187000382A patent/KR102526538B1/ko active Active
- 2016-06-10 KR KR1020247001893A patent/KR20240013282A/ko not_active Ceased
- 2016-06-10 KR KR1020237013832A patent/KR102627811B1/ko active Active
- 2016-06-10 CN CN201680033667.9A patent/CN107709552B/zh active Active
- 2016-06-10 WO PCT/US2016/036991 patent/WO2016201304A1/en not_active Ceased
- 2016-06-10 ES ES16808427T patent/ES2958720T3/es active Active
-
2020
- 2020-07-27 US US16/940,018 patent/US11788059B2/en active Active
-
2021
- 2021-03-09 JP JP2021036808A patent/JP7275178B2/ja active Active
-
2023
- 2023-02-22 JP JP2023025723A patent/JP7836780B2/ja active Active
- 2023-09-07 US US18/463,213 patent/US20240002802A1/en active Pending
-
2025
- 2025-03-24 JP JP2025048124A patent/JP2025089426A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517415A5 (https=) | ||
| Roberts et al. | Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL | |
| JP2024099850A5 (https=) | ||
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| JP2018510881A5 (https=) | ||
| JP2020509767A5 (https=) | ||
| JP2022159548A5 (https=) | ||
| IL278348B1 (en) | Methods and compositions for treating cancer | |
| JP2021514677A5 (https=) | ||
| JP2016520074A5 (https=) | ||
| JP2020516654A5 (https=) | ||
| JP2021508255A5 (https=) | ||
| JP2021522820A5 (https=) | ||
| JP2017513478A5 (https=) | ||
| MX2011012047A (es) | Inmunoglobulinas humanas anti-cd52. | |
| JP2017515460A5 (https=) | ||
| JP2017535292A5 (https=) | ||
| JP2019532625A5 (https=) | ||
| JP2019537433A5 (https=) | ||
| RS63574B1 (sr) | Metode za povećanje efikasnosti imuno ćelija | |
| JP2015527070A5 (https=) | ||
| JP2017509342A5 (https=) | ||
| JP2014518615A5 (https=) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2009539380A5 (https=) |